Duchenne Muscular Dystrophy Drugs Market Report

Global and Region Duchenne Muscular Dystrophy Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 30, 2022
  • PAGES：179
  • REPORT CODE：GMM917141
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death.

    The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.

    The report details the trend, potential and market size of Duchenne Muscular Dystrophy Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Duchenne Muscular Dystrophy Drugsmarket, defines the market attractiveness level of Duchenne Muscular Dystrophy Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Duchenne Muscular Dystrophy Drugs industry, describes the types of Duchenne Muscular Dystrophy Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Duchenne Muscular Dystrophy Drugs market and the development prospects and opportunities of Duchenne Muscular Dystrophy Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Duchenne Muscular Dystrophy Drugs market in Chapter 13.

    By Player:

    • CRISPR Therapeutics

    • WAVE Life Sciences Ltd

    • Biogen Inc

    • Debiopharm International SA

    • Capricor Therapeutics Inc

    • Beech Tree Labs Inc

    • Galapagos NV

    • SOM Biotech SL

    • Taiho Pharmaceutical Co Ltd

    • Antisense Therapeutics Ltd

    • Editas Medicine Inc

    • Teijin Pharma Ltd

    • F Hoffmann-La Roche Ltd

    • BioMarin Pharmaceutical Inc

    • Santhera Pharmaceuticals Holding AG

    • GTx Inc

    • Daiichi Sankyo Co Ltd

    • Sarepta Therapeutics Inc

    • Fulcrum Therapeutics Inc

    • Eloxx Pharmaceuticals Inc

    • Cumberland Pharmaceuticals Inc

    • Akashi Therapeutics Inc

    • Strykagen Corp

    • FibroGen Inc

    • Genethon SA

    • Biophytis SAS

    • Summit Therapeutics Plc

    • Bioleaders Corp

    • Catabasis Pharmaceuticals Inc

    By Type:

    • Development & Drug Target

    • Mechanism of Action (MoA)

    • Route of Administration (RoA)

    • Molecule Type

    By End-User:

    • Hospitals and Clinics

    • Medical Laboratories

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Duchenne Muscular Dystrophy Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Duchenne Muscular Dystrophy Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Duchenne Muscular Dystrophy Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Duchenne Muscular Dystrophy Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Duchenne Muscular Dystrophy Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)

    • 7.2 United States Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)

    • 7.3 Europe Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)

    • 7.4 China Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)

    • 7.5 Japan Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)

    • 7.6 India Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)

    • 7.7 South Korea Duchenne Muscular Dystrophy Drugs Consumption (2017-2022)

    8 Region and Country-wise Duchenne Muscular Dystrophy Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)

    • 8.4 China Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)

    • 8.6 India Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Duchenne Muscular Dystrophy Drugs Consumption Forecast (2022-2028)

    9 Global Duchenne Muscular Dystrophy Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Development & Drug Target Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Mechanism of Action (MoA) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Route of Administration (RoA) Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Molecule Type Consumption and Growth Rate (2017-2022)

    • 9.2 Global Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals and Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Medical Laboratories Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Duchenne Muscular Dystrophy Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Development & Drug Target Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Mechanism of Action (MoA) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Route of Administration (RoA) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Molecule Type Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals and Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Medical Laboratories Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Duchenne Muscular Dystrophy Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Duchenne Muscular Dystrophy Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Duchenne Muscular Dystrophy Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Duchenne Muscular Dystrophy Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Duchenne Muscular Dystrophy Drugs Market Competitive Analysis

    • 14.1 CRISPR Therapeutics

      • 14.1.1 CRISPR Therapeutics Company Details

      • 14.1.2 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.2 WAVE Life Sciences Ltd

      • 14.2.1 WAVE Life Sciences Ltd Company Details

      • 14.2.2 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.3 Biogen Inc

      • 14.3.1 Biogen Inc Company Details

      • 14.3.2 Biogen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.4 Debiopharm International SA

      • 14.4.1 Debiopharm International SA Company Details

      • 14.4.2 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.5 Capricor Therapeutics Inc

      • 14.5.1 Capricor Therapeutics Inc Company Details

      • 14.5.2 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.6 Beech Tree Labs Inc

      • 14.6.1 Beech Tree Labs Inc Company Details

      • 14.6.2 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.7 Galapagos NV

      • 14.7.1 Galapagos NV Company Details

      • 14.7.2 Galapagos NV Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Galapagos NV Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.8 SOM Biotech SL

      • 14.8.1 SOM Biotech SL Company Details

      • 14.8.2 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.9 Taiho Pharmaceutical Co Ltd

      • 14.9.1 Taiho Pharmaceutical Co Ltd Company Details

      • 14.9.2 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.10 Antisense Therapeutics Ltd

      • 14.10.1 Antisense Therapeutics Ltd Company Details

      • 14.10.2 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.11 Editas Medicine Inc

      • 14.11.1 Editas Medicine Inc Company Details

      • 14.11.2 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.12 Teijin Pharma Ltd

      • 14.12.1 Teijin Pharma Ltd Company Details

      • 14.12.2 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.13 F Hoffmann-La Roche Ltd

      • 14.13.1 F Hoffmann-La Roche Ltd Company Details

      • 14.13.2 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.14 BioMarin Pharmaceutical Inc

      • 14.14.1 BioMarin Pharmaceutical Inc Company Details

      • 14.14.2 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.15 Santhera Pharmaceuticals Holding AG

      • 14.15.1 Santhera Pharmaceuticals Holding AG Company Details

      • 14.15.2 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.16 GTx Inc

      • 14.16.1 GTx Inc Company Details

      • 14.16.2 GTx Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 GTx Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.17 Daiichi Sankyo Co Ltd

      • 14.17.1 Daiichi Sankyo Co Ltd Company Details

      • 14.17.2 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.18 Sarepta Therapeutics Inc

      • 14.18.1 Sarepta Therapeutics Inc Company Details

      • 14.18.2 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.18.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.19 Fulcrum Therapeutics Inc

      • 14.19.1 Fulcrum Therapeutics Inc Company Details

      • 14.19.2 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.19.3 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.20 Eloxx Pharmaceuticals Inc

      • 14.20.1 Eloxx Pharmaceuticals Inc Company Details

      • 14.20.2 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.20.3 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.21 Cumberland Pharmaceuticals Inc

      • 14.21.1 Cumberland Pharmaceuticals Inc Company Details

      • 14.21.2 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.21.3 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.22 Akashi Therapeutics Inc

      • 14.22.1 Akashi Therapeutics Inc Company Details

      • 14.22.2 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.22.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.23 Strykagen Corp

      • 14.23.1 Strykagen Corp Company Details

      • 14.23.2 Strykagen Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.23.3 Strykagen Corp Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.24 FibroGen Inc

      • 14.24.1 FibroGen Inc Company Details

      • 14.24.2 FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.24.3 FibroGen Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.25 Genethon SA

      • 14.25.1 Genethon SA Company Details

      • 14.25.2 Genethon SA Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.25.3 Genethon SA Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.26 Biophytis SAS

      • 14.26.1 Biophytis SAS Company Details

      • 14.26.2 Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.26.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.27 Summit Therapeutics Plc

      • 14.27.1 Summit Therapeutics Plc Company Details

      • 14.27.2 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.27.3 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.28 Bioleaders Corp

      • 14.28.1 Bioleaders Corp Company Details

      • 14.28.2 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.28.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Product and Service

    • 14.29 Catabasis Pharmaceuticals Inc

      • 14.29.1 Catabasis Pharmaceuticals Inc Company Details

      • 14.29.2 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.29.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Duchenne Muscular Dystrophy Drugs

    • Figure Duchenne Muscular Dystrophy Drugs Picture

    • Table Global Duchenne Muscular Dystrophy Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Duchenne Muscular Dystrophy Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Duchenne Muscular Dystrophy Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Duchenne Muscular Dystrophy Drugs Consumption by Country (2017-2022)

    • Figure United States Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Duchenne Muscular Dystrophy Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Duchenne Muscular Dystrophy Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Development & Drug Target Consumption and Growth Rate (2017-2022)

    • Figure Global Mechanism of Action (MoA) Consumption and Growth Rate (2017-2022)

    • Figure Global Route of Administration (RoA) Consumption and Growth Rate (2017-2022)

    • Figure Global Molecule Type Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals and Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Medical Laboratories Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Development & Drug Target Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Mechanism of Action (MoA) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Route of Administration (RoA) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Molecule Type Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals and Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Medical Laboratories Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Duchenne Muscular Dystrophy Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Duchenne Muscular Dystrophy Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table CRISPR Therapeutics (Foundation Year, Company Profile and etc.)

    • Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Product and Service

    • Table WAVE Life Sciences Ltd (Foundation Year, Company Profile and etc.)

    • Table WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Biogen Inc (Foundation Year, Company Profile and etc.)

    • Table Biogen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biogen Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Debiopharm International SA (Foundation Year, Company Profile and etc.)

    • Table Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Debiopharm International SA Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Capricor Therapeutics Inc (Foundation Year, Company Profile and etc.)

    • Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Beech Tree Labs Inc (Foundation Year, Company Profile and etc.)

    • Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Galapagos NV (Foundation Year, Company Profile and etc.)

    • Table Galapagos NV Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Galapagos NV Duchenne Muscular Dystrophy Drugs Product and Service

    • Table SOM Biotech SL (Foundation Year, Company Profile and etc.)

    • Table SOM Biotech SL Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table SOM Biotech SL Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Taiho Pharmaceutical Co Ltd (Foundation Year, Company Profile and etc.)

    • Table Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Antisense Therapeutics Ltd (Foundation Year, Company Profile and etc.)

    • Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Editas Medicine Inc (Foundation Year, Company Profile and etc.)

    • Table Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Teijin Pharma Ltd (Foundation Year, Company Profile and etc.)

    • Table Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • Table F Hoffmann-La Roche Ltd (Foundation Year, Company Profile and etc.)

    • Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • Table BioMarin Pharmaceutical Inc (Foundation Year, Company Profile and etc.)

    • Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Santhera Pharmaceuticals Holding AG (Foundation Year, Company Profile and etc.)

    • Table Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Product and Service

    • Table GTx Inc (Foundation Year, Company Profile and etc.)

    • Table GTx Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table GTx Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Daiichi Sankyo Co Ltd (Foundation Year, Company Profile and etc.)

    • Table Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Sarepta Therapeutics Inc (Foundation Year, Company Profile and etc.)

    • Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Fulcrum Therapeutics Inc (Foundation Year, Company Profile and etc.)

    • Table Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Eloxx Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Cumberland Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Akashi Therapeutics Inc (Foundation Year, Company Profile and etc.)

    • Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Strykagen Corp (Foundation Year, Company Profile and etc.)

    • Table Strykagen Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Strykagen Corp Duchenne Muscular Dystrophy Drugs Product and Service

    • Table FibroGen Inc (Foundation Year, Company Profile and etc.)

    • Table FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table FibroGen Inc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Genethon SA (Foundation Year, Company Profile and etc.)

    • Table Genethon SA Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genethon SA Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Biophytis SAS (Foundation Year, Company Profile and etc.)

    • Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Summit Therapeutics Plc (Foundation Year, Company Profile and etc.)

    • Table Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Bioleaders Corp (Foundation Year, Company Profile and etc.)

    • Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Product and Service

    • Table Catabasis Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US